hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-14. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
The oldest-known fossil among the Eutheria ("true beasts") is the small shrewlike Juramaia sinensis, or "Jurassic mother from China", dated to 160 million years ago in the late Jurassic. A later eutherian relative, Eomaia, dated to 125 million years ago in the early Cretaceous, possessed some features in common with the marsupials but not with the placentals, evidence that these features were present in the last common ancestor of the two groups but were later lost in the placental lineage. In particular, the epipubic bones extend forwards from the pelvis. These are not found in any modern placental, but they are found in marsupials, monotremes, other nontherian mammals and Ukhaatherium, an early Cretaceous animal in the eutherian order Asioryctitheria. This also applies to the multituberculates. They are apparently an ancestral feature, which subsequently disappeared in the placental lineage. These epipubic bones seem to function by stiffening the muscles during locomotion, reducing the amount of space being presented, which placentals require to contain their fetus during gestation periods. A narrow pelvic outlet indicates that the young were very small at birth and therefore pregnancy was short, as in modern marsupials. This suggests that the placenta was a later development. One of the earliest-known monotremes was Teinolophos, which lived about 120 million years ago in Australia.
== Function == As their names suggests, the Prolyl 3-hydroxylase 2 and its relatives Prolyl 3-hydroxylase 1 and 3 function as collagen prolyl 3-hydroxylases. This means they act on the amino acid, proline, located in collagen precursor proteins, and attach a hydroxyl at the 3-position, converting the proline into 3-hydroxyproline. This seems to function to help the corresponding collagen fibrils bind together and align properly. P3H2 differs from P3H1 in a number of important ways. It is primarily expressed in basement membrane-rich tissues (P3H1 is primarily in fibrillar collagens rich tissues). It is also able to act on type IV collagen (especially COL4A1), unlike P3H1. Both enzymes are able to act on Type I collagen (and COL1A1), but they tend to modify the prolines at different positions. P3H2 also appears to function on its own, while P3H1 forms a complex with two other proteins (CRTAP and CypB).
== Side-effects == Remifentanil is a specific μ-receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia. The drug's effects include a dose-dependent decrease in heart rate and arterial pressure and respiratory rate and tidal volume. Muscle rigidity is sometimes noted. The most common side effects reported by patients receiving this medication are a sense of extreme "dizziness" (often short lived, a common side effect of other fast-acting synthetic phenylpiperidine narcotics such as fentanyl and alfentanil) and intense itching (pruritus), often around the face. These side effects are often controlled by either altering the administered dose (decreasing or in some cases, increasing the dose) or by administering other sedatives that allow the patient to tolerate or lose awareness of the side effect. Because pruritus is partially due to excessive serum histamine levels, antihistamines such as diphenhydramine (Benadryl) are often co-administered. This is done with care, however, as excessive sedation may occur. Nausea can occur as a side effect of remifentanil, however, it is usually transient in nature due to the drug's short half-life which rapidly removes it from the patient's circulation once the infusion is terminated.
YouTube, Facebook and others use recommender systems to guide users to more content. These AI programs were given the goal of maximising user engagement (that is, the only goal was to keep people watching). The AI learned that users tended to choose misinformation, conspiracy theories, and extreme partisan content, and, to keep them watching, the AI recommended more of it. Users also tended to watch more content on the same subject, so the AI led people into filter bubbles where they received multiple versions of the same misinformation. This convinced many users that the misinformation was true, and ultimately undermined trust in institutions, the media and the government. The AI program had correctly learned to maximise its goal, but the result was harmful to society. After the U.S. election in 2016, major technology companies took some steps to mitigate the problem. In the early 2020s, generative AI began to create images, audio, and texts that are virtually indistinguishable from real photographs, recordings, or human writing, while realistic AI-generated videos became feasible in the mid-2020s. It is possible for bad actors to use this technology to create massive amounts of misinformation and computational propaganda through techniques such as deepfakes. AI pioneer and Nobel Prize-winning computer scientist Geoffrey Hinton expressed concern about AI enabling "authoritarian leaders to manipulate their electorates" on a large scale, among other risks. The ability to influence electorates has been proved in at least one study.
Evidence from the study of extant and extinct canids interpreted as supporting Bergmann's rule in the studied group at the interspecific level is presented by Chaves-Silveira et al. (2026). Evidence from the study of the fossil record of canids from the John Day Formation, indicative of stronger links of dietary behavior of the studied canids (as indicated by tooth wear) with lineage duration than with tooth morphology, is presented by Tanis, DeSantis & Terry (2026). Kort, Cavin & Wang (2026) describe the anatomy of the postcranial skeleton of Mesocyon coryphaeus, finding no evidence of cursorial adaptations seen in later canids, and interpret the studied canid as a likely ambush predator. Kropczyk & Marciszak (2026) report the discovery of fossil material of the corsac fox from the late Pleistocene strata from the Rogóżka Cave (Poland). Fossil material of Xenocyon lycaonoides representing one of the earliest records of this species worldwide is described from the early Pleistocene strata from the Gonghe Basin (Tibetan Plateau; China) by Huang et al. (2026). Frosali et al. (2026) interpret the shape and size of the frontal sinus in Canis etruscus, Canis mosbachensis and Canis borjgali as primarily influenced by the ecology of the studied canids, and interpret the morphology of the frontal sinus of the latter two species as indicative of higher proportion of meat in their diets compared to C. etruscus.
Sources: en.wikipedia.org
=== Hormonal factors === Hormones play a dominant role in the formation of cellulite. Estrogen is thought to be an important hormone in the development of cellulite, and it has been proposed that an imbalance of estrogen relative to progesterone may be associated with cellulite. However, there has been no reliable clinical evidence to support the claim that estrogen levels are linked to cellulite, and many women with elevated estrogen levels do not get cellulite. Other hormones—including insulin, the catecholamines adrenaline, cortisol and noradrenaline, thyroid hormones, and prolactin—are believed to participate in the development of cellulite.
are all constants, provides a good fit to experimental data over the entire range of temperatures, while at the same time reducing to the correct Arrhenius form in the low and high temperature limits. This expression, also known as Duouglas-Doremus-Ojovan model, can be motivated from various theoretical models of amorphous materials at the atomic level. A two-exponential equation for the viscosity can be derived within the Dyre shoving model of supercooled liquids, where the Arrhenius energy barrier is identified with the high-frequency shear modulus times a characteristic shoving volume. Upon specifying the temperature dependence of the shear modulus via thermal expansion and via the repulsive part of the intermolecular potential, another two-exponential equation is retrieved:
Ross (1952), engineer and managing partner at Jaros, Baum & Bolles William Carl Burger (1953), botanist, curator at the Field Museum of Natural History Gerald Feinberg (1953), physicist who coined the term "tachyon" Bernard Friedland (1953), professor and engineer, New Jersey Institute of Technology, recipient of the 1982 Rufus Oldenburger Medal Arthur Gottlieb (1953), immunologist, professor at Tulane University School of Medicine Eliot S. Hearst (1953), psychologist, professor at Indiana University Charles Kadushin (1953), psychologist at the City University of New York, recipient of the 2009 Marshall Sklare Award Donald R. Olander (1953), professor of nuclear engineering at University of California, Berkeley Nicholas P. Samios (1953), former director of the Brookhaven National Laboratory Melvin Schwartz (1953), winner of the Nobel Prize in Physics in 1988 Wallace Smith Broecker (1953), professor of environmental science at Columbia University, developed the idea of a global "conveyor belt" linking ocean circulation Richard K. Bernstein (1954), physician and advocate for low-carbohydrate diet Henry Buchwald (1954), professor of surgery and biomedical engineering at University of Minnesota Neil D. Opdyke (1955), geologist Alvin F. Poussaint (1956), professor of psychiatry and dean of freshmen at the Harvard Medical School A.
=== 2006–2010 === In 2006, Sonic Healthcare acquired Central Queensland Pathology Laboratory (Mackay, Queensland) merging it with Sullivan Nicolaides Pathology, Muskogee Clinical Laboratory (Muskogee, Oklahoma, US), The Cognoscenti Health Institute (East Orlando, Florida, US), and Lookadoo Skyline Laboratories (Port St Lucie, Florida, US). Bioscientia Healthcare Group based in Ingelheim, Germany, August 2007. In 2007, the company acquired American Esoteric Laboratories (Tennessee and Texas), the remaining 18% of Clinical Pathology Laboratories, Mullins Pathology & Cytology Laboratory P.C., Augusta, Georgia, US, Sunrise Medical Laboratories, a full-service clinical reference laboratory servicing Long Island and the New York metropolitan area, and Woodbury Clinical Laboratory in Lebanon, Tennessee. That same year, in Europe, the Medica Laboratory Group, based in Zurich, Switzerland, the Bioscientia Healthcare Group in Ingelheim, Germany, and the remaining equity in the Schottdorf Group were acquired. In Australia, Sonic Healthcare acquired LifeCheck (Sydney, NSW), merging it into Lifescreen. In 2008, in the US, Sonic Healthcare acquired American Clinical Services (New Jersey) merging it with Sunrise Medical Laboratories, Clinical Laboratories of Hawaii, and Pan Pacific Pathologists (Hawaii). In Europe, it acquired Labor Prof. Krech (Switzerland) merging it into Medica, Labor 28 (Berlin, Germany), GLP Medical Group (Hamburg, Germany), and 100% ownership of IPN which in turn acquired the Gemini Medical Group.
In 2016, the World Health Organization estimated that 34 million people used opioids and 19 million used opiates. Of these, about 27 million people had opioid dependence, with the majority—but a decreasing number—using illicit heroin. In 2015, 118,000 people died from opioid use disorders, causing almost one-third of all drug-related deaths.
Sources: en.wikipedia.org
Bisoprolol is used for prevention of cardiovascular events following a heart attack in patients with risk factors for disease progression, in the management of congestive heart failure with reduced ejection fraction, and as a second-line agent for hypertension. Bisoprolol may be beneficial in the treatment of high blood pressure, but it is not recommended as a first-line antihypertensive agent. It can be an adjunct to first-line antihypertensive agents in patients with accompanying comorbidities, for example, congestive heart failure, where selected beta blockers can be added in patients who remain mildly to moderately symptomatic despite appropriate doses of an angiotensin-converting-enzyme inhibitor. In cardiac ischemia, the drug is used to reduce the activity of the heart muscle, thereby reducing its oxygen and nutrient demands and allowing its reduced blood supply to still transport sufficient amounts of oxygen and nutrients to meet its needs.
3 April – NASA selects three companies – Intuitive Machines, Lunar Outpost and Venturi Astrolab – to develop its Lunar Terrain Vehicle, for use in crewed Artemis missions from 2030 onwards. 4 April A study in Nature finds that global CO2 emissions increased by only 0.1% in 2023, suggesting that a plateau may have been reached. The Dark Energy Spectroscopic Instrument (DESI) project releases multiple papers which report unprecedented measurements of dark energy, find indications that dark energy which is expanding the Universe is evolving over time, and release the most detailed largest 3D cosmic map to date. 5 April – A numerical toolkit designed for modelling warp drive spacetimes is introduced in Classical and Quantum Gravity. 9 April – A rare genetic variation in a gene that makes fibronectin is shown to reduce the odds of developing Alzheimer's disease by over 70%. 11 April – The first nitrogen-fixing organelle in a marine alga is reported, the nitroplast. The early evolutionary stage organelle provides a view into the transition from an endosymbiont into a proper organelle that receives about half of its proteins from the alga. 12 April Biologists report that bonobos behave more aggressively than thought earlier. Scientists describe how tardigrades are protecting themselves from large radiation exposure and damage, which is quickly repaired, using the Dsup protein. 15 April The NOAA confirms a fourth global coral bleaching event. The world's first commercial-scale factory producing sustainable high-protein food from air, microbes and solar energy, Solein, launches.
While dichloroacetylene is nephrotoxic in rats, its nephrotoxicity in humans is not well-understood. Dichloroacetylene has mutagenic effects on Salmonella typhimurium. Like trichloroethylene, dichloroacetylene is metabolized to S-(1,2-dichlorovinyl)-L-cysteine (DCVC) in vivo. The maximum safe concentration of dichloroacetylene in air is 0.1 parts per million. It is unsafe to store dichloroacetylene in close proximity to potassium, sodium, or aluminium powder. According to the Department of Transportation, it is forbidden to ship dichloroacetylene.
17α-Alkylation: methyltestosterone, metandienone, fluoxymesterone, oxandrolone, oxymetholone, stanozolol, norethandrolone, ethylestrenol 19-Demethylation: nandrolone, trenbolone, norethandrolone, ethylestrenol, trestolone, dimethandrolone 5α-Reduction: androstanolone, drostanolone, mestanolone, mesterolone, metenolone, oxandrolone, oxymetholone, stanozolol 3β- and/or 17β-esterification: testosterone enanthate, nandrolone decanoate, drostanolone propionate, boldenone undecylenate, trenbolone acetate As well as others such as 1-dehydrogenation (e.g., metandienone, boldenone), 1-substitution (e.g., mesterolone, metenolone), 2-substitution (e.g., drostanolone, oxymetholone, stanozolol), 4-substitution (e.g., clostebol, oxabolone), and various other modifications.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.